Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. (Q53350484)

13 May 2018

review article

1 reference

title

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. (English)

1 reference

13 May 2018

author name string

A Goldhirsch

1

1 reference

13 May 2018

J H Glick

2

1 reference

13 May 2018

R D Gelber

3

1 reference

13 May 2018

H J Senn

4

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 November 1998

1 reference

13 May 2018

Journal of the National Cancer Institute

published in

1 reference

13 May 2018

volume

90

1 reference

13 May 2018

issue

21

1 reference

13 May 2018

page(s)

1601-1608

1 reference

13 May 2018

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Much ado about not...enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the Nationa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

A cancer therapy resistant to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F90.21.1601

21 January 2018

Identifiers

DOI

10.1093/JNCI/90.21.1601

1 reference

13 May 2018

PubMed ID

9811309

1 reference

13 May 2018